Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Rochester, NY
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Fayetteville, NC
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Fayetteville, NC
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
New Bern, NC
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
New Bern, NC
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Bismarck, ND
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Cincinnati, OH
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Middletown, OH
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Zanesville, OH
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Zanesville, OH
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Coos Bay, OR
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Coos Bay, OR
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Hilton Head Island, SC
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Hilton Head Island, SC
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Chattanooga, TN
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Knoxville, TN
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Nashville, TN
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Austin, TX
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
White River Junction, VT
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
White River Junction, VT
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Abingdon, VA
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Abingdon, VA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Clinical Research Facility
mi
from
Alexandria, VA
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/13/2017
Research Site
mi
from
Armidale,
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/13/2017
Research Site
mi
from
Armidale,
Click here to add this to my saved trials
Study of Patient Navigation to Promote Colon Cancer Screening
Randomized Controlled Trial of Patient Navigation to Increase Colorectal Cancer Screening Rates Among Community Health Center Patients
Status: Enrolling
Updated:  4/17/2017
Cambridge Health Alliance
mi
from
Cambridge, MA
Study of Patient Navigation to Promote Colon Cancer Screening
Randomized Controlled Trial of Patient Navigation to Increase Colorectal Cancer Screening Rates Among Community Health Center Patients
Status: Enrolling
Updated: 4/17/2017
Cambridge Health Alliance
mi
from
Cambridge, MA
Click here to add this to my saved trials
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  4/18/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 4/18/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  4/18/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 4/18/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  4/18/2017
The Mayo Clinic
mi
from
Rochester, MN
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 4/18/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
IFACT: Incidental Findings in Advanced Cancer Therapy
IFACT: Incidental Findings in Advanced Cancer Therapy
Status: Enrolling
Updated:  4/19/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
IFACT: Incidental Findings in Advanced Cancer Therapy
IFACT: Incidental Findings in Advanced Cancer Therapy
Status: Enrolling
Updated: 4/19/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
Cancer Prevention and Treatment Among African American Older Adults
Status: Enrolling
Updated:  4/19/2017
Bloomberg School of Public Health
mi
from
Baltimore, MD
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
Cancer Prevention and Treatment Among African American Older Adults
Status: Enrolling
Updated: 4/19/2017
Bloomberg School of Public Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Experimental Device to Improve Colonoscopy
A Trial of Segmental Stiffening Wires to Improve the Efficiency and Patient Tolerability of Colonoscopy
Status: Enrolling
Updated:  4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Experimental Device to Improve Colonoscopy
A Trial of Segmental Stiffening Wires to Improve the Efficiency and Patient Tolerability of Colonoscopy
Status: Enrolling
Updated: 4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer
Status: Enrolling
Updated:  5/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer
Status: Enrolling
Updated: 5/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Initiation of Colon Cancer Screening in Veterans or "Start Screening Now"
Initiation of Colon Cancer Screening in Veterans
Status: Enrolling
Updated:  5/2/2017
University of Texas Health Science Center at Houston School of Public Health
mi
from
Houston, TX
Initiation of Colon Cancer Screening in Veterans or "Start Screening Now"
Initiation of Colon Cancer Screening in Veterans
Status: Enrolling
Updated: 5/2/2017
University of Texas Health Science Center at Houston School of Public Health
mi
from
Houston, TX
Click here to add this to my saved trials
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.
Status: Enrolling
Updated:  5/8/2017
Siteman Cancer Center, Washington University Medical School
mi
from
Saint Louis, MO
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.
Status: Enrolling
Updated: 5/8/2017
Siteman Cancer Center, Washington University Medical School
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.
Status: Enrolling
Updated:  5/8/2017
Aalborg Universitetshospital
mi
from
Aalborg,
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.
Status: Enrolling
Updated: 5/8/2017
Aalborg Universitetshospital
mi
from
Aalborg,
Click here to add this to my saved trials
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/9/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/9/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Patient Preferences of a Resect and Discard Paradigm
Patient Preferences of a Resect and Discard Paradigm
Status: Enrolling
Updated:  5/10/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
Patient Preferences of a Resect and Discard Paradigm
Patient Preferences of a Resect and Discard Paradigm
Status: Enrolling
Updated: 5/10/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
Status: Enrolling
Updated:  5/18/2017
New York State Psychiatric Institute
mi
from
New York, NY
A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
Status: Enrolling
Updated: 5/18/2017
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated:  5/22/2017
University of Chicago
mi
from
Chicago, IL
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated: 5/22/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated:  5/22/2017
CRO-National Cancer Institute
mi
from
Aviano,
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status: Enrolling
Updated: 5/22/2017
CRO-National Cancer Institute
mi
from
Aviano,
Click here to add this to my saved trials
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated:  5/23/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated: 5/23/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Clackamas Radiation Oncology Center
mi
from
Clackamas, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Clackamas Radiation Oncology Center
mi
from
Clackamas, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Newberg Medical Center
mi
from
Newberg, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Newberg Medical Center
mi
from
Newberg, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Willamette Falls Medical Center
mi
from
Oregon City, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Willamette Falls Medical Center
mi
from
Oregon City, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Portland Medical Center
mi
from
Portland, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Oregon Health and Science University
mi
from
Portland, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
PeaceHealth Southwest Medical Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated:  5/23/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Enrolling
Updated: 5/23/2017
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials